Olga Koval1,2,*, Maria Zhilnikova1, Maria Balantaeva1,2, Mikhail Biryukov1,2, Vasiliy Atamanov1,3
BIOCELL, Vol.49, No.3, pp. 355-379, 2025, DOI:10.32604/biocell.2025.059987
- 31 March 2025
Abstract Melanomas are aggressive cancers, with a high rate of metastatic disease. Cutaneous (CM) and uveal (UM) melanomas are intrinsically different diseases, and most cell death inducers effective for CM do not function for UM. This is primarily due to the fact the eye is an immunologically privileged organ, and it fails to achieve the efficacy of immune checkpoint inhibitors (ICIs) comparable to that for CM. However, approaches utilizing specific melanoma-associated antigens are being developed for metastatic forms of CM and UM. The most promising to date are gp100 and tyrosinase related protein 1 (TYRP1), primarily… More >